FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases (Q34585773)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 8, 2011

Language	Label	Description	Also known as
English	FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases	scientific article published on February 8, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases (English)

1 reference

10.1186/1756-9966-30-16

https://api.crossref.org/works/10.1186/1756-9966-30-16

23 November 2024

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Francesco Pisani

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Carlo Ludovico Maini

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Rosa Sciuto

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Laura Dessanti

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Mariella D'Andrea

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Daniela Assisi

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Maria Concetta Petti

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

8 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

full work available at URL

https://jeccr.biomedcentral.com/track/pdf/10.1186/1756-9966-30-16

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21303501

23 November 2024

https://europepmc.org/articles/PMC3041690

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21303501

23 November 2024

https://europepmc.org/articles/PMC3041690?pdf=render

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21303501

23 November 2024

http://link.springer.com/content/pdf/10.1186/1756-9966-30-16.pdf

1 reference

10.1186/1756-9966-30-16

https://api.crossref.org/works/10.1186/1756-9966-30-16

23 November 2024

http://link.springer.com/article/10.1186/1756-9966-30-16/fulltext.html

1 reference

10.1186/1756-9966-30-16

https://api.crossref.org/works/10.1186/1756-9966-30-16

23 November 2024

Journal of Experimental & Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

8 February 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma--role of radioimmunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

7 July 2018

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

27 October 2018

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

27 October 2018

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

27 October 2018

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

27 October 2018

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3041690

27 October 2018

Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21303501

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-9966-30-16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

release_fu2r7lzwkfhc5iobtl5dffcnpq

1 reference

https://api.fatcat.wiki/v0/release/fu2r7lzwkfhc5iobtl5dffcnpq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34585773&oldid=2279611376"